WO2005040790A3 - Diagnostics and therapeutics for diseases associated with g protein-coupled receptor 75 (gpr75) - Google Patents

Diagnostics and therapeutics for diseases associated with g protein-coupled receptor 75 (gpr75) Download PDF

Info

Publication number
WO2005040790A3
WO2005040790A3 PCT/EP2004/011389 EP2004011389W WO2005040790A3 WO 2005040790 A3 WO2005040790 A3 WO 2005040790A3 EP 2004011389 W EP2004011389 W EP 2004011389W WO 2005040790 A3 WO2005040790 A3 WO 2005040790A3
Authority
WO
WIPO (PCT)
Prior art keywords
disorders
gpr75
therapeutics
diagnostics
protein
Prior art date
Application number
PCT/EP2004/011389
Other languages
French (fr)
Other versions
WO2005040790A2 (en
Inventor
Stefan Golz
Ulf Brueggemeier
Andreas Geerts
Holger Summer
Original Assignee
Bayer Healthcare Ag
Stefan Golz
Ulf Brueggemeier
Andreas Geerts
Holger Summer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Healthcare Ag, Stefan Golz, Ulf Brueggemeier, Andreas Geerts, Holger Summer filed Critical Bayer Healthcare Ag
Publication of WO2005040790A2 publication Critical patent/WO2005040790A2/en
Publication of WO2005040790A3 publication Critical patent/WO2005040790A3/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57442—Specifically defined cancers of the uterus and endometrial
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57446—Specifically defined cancers of stomach or intestine
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57449—Specifically defined cancers of ovaries

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Reproductive Health (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The invention provides a human GPR75 which is associated with the cardiovascular disorders, dermatological disorders, gastrointestinal and liver diseases, cancer disorders, neurological disorders and urological disorders. The invention also provides assays for the identification of compounds useful in the treatment or prevention of cardiovascular disorders, dermatological disorders, gastrointestinal and liver diseases, cancer disorders, neurological disorders and urological disorders. The invention also features compounds which bind to and/or activate or inhibit the activity of GPR75 as well as pharmaceutical compositions comprising such compounds.
PCT/EP2004/011389 2003-10-24 2004-10-12 Diagnostics and therapeutics for diseases associated with g protein-coupled receptor 75 (gpr75) WO2005040790A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP03024488.3 2003-10-24
EP03024488 2003-10-24

Publications (2)

Publication Number Publication Date
WO2005040790A2 WO2005040790A2 (en) 2005-05-06
WO2005040790A3 true WO2005040790A3 (en) 2005-11-10

Family

ID=34486105

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2004/011389 WO2005040790A2 (en) 2003-10-24 2004-10-12 Diagnostics and therapeutics for diseases associated with g protein-coupled receptor 75 (gpr75)

Country Status (1)

Country Link
WO (1) WO2005040790A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015017656A1 (en) * 2013-07-31 2015-02-05 The Regents Of The University Of California Methods of diagnosis and treatment for pulmonary arterial hypertension
AU2021296270A1 (en) * 2020-06-22 2023-02-02 Regeneron Pharmaceuticals, Inc. Treatment of obesity with G-protein coupled receptor 75 (GPR75) inhibitors

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000024888A1 (en) * 1998-10-26 2000-05-04 Multigene Biotech Gmbh CDNA SEQUENCE AND GENOMIC ORGANIZATION FOR A 59.4 KDA NEURONAL-SPECIFIC 7 TRANSMEMBRANE PROTEIN (pNEU60)
WO2002061087A2 (en) * 2000-12-19 2002-08-08 Lifespan Biosciences, Inc. Antigenic peptides, such as for g protein-coupled receptors (gpcrs), antibodies thereto, and systems for identifying such antigenic peptides

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000024888A1 (en) * 1998-10-26 2000-05-04 Multigene Biotech Gmbh CDNA SEQUENCE AND GENOMIC ORGANIZATION FOR A 59.4 KDA NEURONAL-SPECIFIC 7 TRANSMEMBRANE PROTEIN (pNEU60)
WO2002061087A2 (en) * 2000-12-19 2002-08-08 Lifespan Biosciences, Inc. Antigenic peptides, such as for g protein-coupled receptors (gpcrs), antibodies thereto, and systems for identifying such antigenic peptides

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
TARTTELIN E E ET AL: "Cloning and characterization of a novel orphan G-protein receptor localized to human chromosome 2p16", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, ACADEMIC PRESS INC. ORLANDO, FL, US, vol. 260, no. 1, 24 June 1999 (1999-06-24), pages 174 - 180, XP002129506, ISSN: 0006-291X *

Also Published As

Publication number Publication date
WO2005040790A2 (en) 2005-05-06

Similar Documents

Publication Publication Date Title
WO2005093092A3 (en) Diagnostics and therapeutics for diseases associated with g-protein coupled receptor 44 (gpr44)
WO2005095973A3 (en) Diagnostics and therapeutics for diseases associated with g-protein coupled receptor 54 (gpr54)
WO2005040828A3 (en) Diagnostics and therapeutics for diseases associated with g protein-coupled receptor 49 (gpr49)
WO2004080373A3 (en) Diagnostics and therapeutics for diseases associated with g-protein coupled proteinase activated receptor 2 (par2)
WO2005050225A3 (en) Diagnostics and therapeutics for diseases associated with g protein-coupled receptor 84 (gpr84)
WO2004082568A3 (en) Diagnostics and therapeutics for diseases associated with complement component 5a receptor (c5ar)
WO2005093091A3 (en) Diagnostics and therapeutics for diseases associated with g-protein coupled receptor 26 (gpr26)
WO2005040211A3 (en) Diagnostics and therapeutics for diseases associated with g protein-coupled receptor 1 (gpr1)
WO2005059546A3 (en) Diagnostics and therapeutics for diseases associated with g protein-coupled receptor 35 (gpr35)
WO2005040790A3 (en) Diagnostics and therapeutics for diseases associated with g protein-coupled receptor 75 (gpr75)
WO2004104574A3 (en) Diagnostics and therapeutics for diseases associated with c-c chemokine receptor type 7 (ccr7)
WO2005040825A3 (en) Diagnostics and therapeutics for diseases associated with g protein-coupled receptor 20 (gpr20)
WO2004082571A3 (en) Diagnostics and therapeutics for diseases associated with g protein-coupled receptor 86 (gpr86)
WO2004038405A3 (en) Diagnostics and therapeutics for diseases associated with g protein-coupled receptor 43 (gpr43)
WO2005108998A3 (en) Diagnostics and therapeutics for diseases associated with g protein-coupled receptor beta-3 adreno (adrb3)
WO2004099248A3 (en) Diagnostics and therapeutics for diseases associated with g-protein-coupled receptor agtr2 (agtr2)
WO2004081563A3 (en) Diagnostics and therapeutics for diseases associated with phosphodiesterase 1a (pde1a)
WO2004106935A3 (en) Diagnostics and therapeutics for diseases associated with g protein-coupled receptor 103 (gpr103)
WO2004080374A3 (en) Diagnostics and therapeutics for diseases associated with phosphodi-esterase 1c (pde1c)
WO2005040824A3 (en) Diagnostics and therapeutics for diseases associated with g protein-coupled receptor 24 (gpr24)
WO2004082572A3 (en) Diagnostics and therapeutics for diseases associated with g protein-coupled receptor 87 (gpr87)
WO2005040829A3 (en) Diagnostics and therapeutics for diseases associated with g protein-coupled receptor 17 (gpr17)
WO2005003762A3 (en) Diagnostics and therapeutics for diseases associated with sensory neuron-specific g protein-coupled receptor 2 (snsr2)
WO2004038421A3 (en) Diagnostics and therapeutics for diseases associated with human g protein-coupled receptor 41 (gpr41)
WO2005040822A3 (en) Diagnostics and therapeutics for diseases associated with g protein-coupled receptor 25 (gpr25)

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase